Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future-Reference-Cited by-同舟云学术

Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future

Published:2018-01-25 Issue:6 Volume:38 Page:790-800
ISSN:0260-437X
Container-title:Journal of Applied Toxicology
language:en
Short-container-title:J Appl Toxicol

Author:

Yang Baichun¹^ORCID,Papoian Thomas¹

Affiliation:

1. Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research; Food and Drug Administration; 10903 New Hampshire Avenue Silver Spring MD 20993 USA

Publisher

Wiley

Subject

Toxicology

Reference37 articles.

1. Oncogenic kinase signaling;Blume-Jensen;Nature,2001

2. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics;Chen;Circulation,2008

3. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics;Cheng;Circulation Research,2010

4. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity;Cheng;Circulation Research,2011

5. Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury;Cross;British Journal of Pharmacology,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact;Scientific Reports;2023-08-25

2. Prediction and Experimental Evaluation of the hERG Blocking Potential of Drugs Showing Clinical Signs of Cardiotoxicity;Letters in Drug Design & Discovery;2022-08-04

3. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection;Frontiers in Cardiovascular Medicine;2022-04-15

4. In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation;Journal of Cardiovascular Translational Research;2022-03-21

5. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications;Current Oncology Reports;2022-02-18